Edition:
United Kingdom

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

18.99USD
15 Dec 2017
Change (% chg)

$0.76 (+4.17%)
Prev Close
$18.23
Open
$18.29
Day's High
$19.44
Day's Low
$18.29
Volume
184,135
Avg. Vol
37,916
52-wk High
$23.35
52-wk Low
$8.00

Latest Key Developments (Source: Significant Developments)

Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Protagonist Therapeutics Inc : :Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200.Protagonist Therapeutics - co is developing PTG-200 in collaboration with Janssen.  Full Article

Protagonist Therapeutics Q3 ‍net loss per share $0.29​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update.Protagonist Therapeutics Inc qtrly ‍net loss per share attributable to common stockholders was $0.29​.  Full Article

Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Prices public offering of common stock.Says public offering of 3.53 million common shares priced at $17.00 per share.  Full Article

Protagonist Therapeutics announces proposed public offering of common stock
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics announces proposed public offering of common stock.Protagonist Therapeutics -to use proceeds to fund clinical research, development of co's three therapeutic candidates, PTG-100, PTG-200, and PTG-300​.  Full Article

Lilly Ventures Fund I reports 12.9 percent stake in Protagonist Therapeutics Inc as of Aug. 16
Friday, 26 Aug 2016 

Protagonist Therapeutics Inc : Lilly Ventures Fund I LLC reports 12.9 pct stake in Protagonist Therapeutics Inc as of August 16- Sec filing .Lilly Ventures Fund I LLC reports 12.9 pct stake in Protagonist Therapeutics Inc as of August 16 -Sec filing.  Full Article

Ra Capital reports 6.8 pct passive stake in Protagonist Therapeutics
Thursday, 25 Aug 2016 

Protagonist Therapeutics Inc : RA Capital Management LLC reports 6.8 percent passive stake in Protagonist Therapeutics Inc as of August 16 - SEC filing Source: (http://bit.ly/2bDvmY3) Further company coverage: [PTGX.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Adage Capital Partners reports 9.69 pct passive stake in Protagonist Therapeutics - SEC filing
Friday, 19 Aug 2016 

Adage Capital Partners LP:Adage Capital Partners LP reports 9.69 pct passive stake in Protagonist Therapeutics Inc as of August 11, 2016 - SEC filing.  Full Article

Johnson & Johnson reports 15 pct passive stake in Protagonist Therapeutics - SEC filing
Friday, 19 Aug 2016 

Johnson & Johnson:Johnson & Johnson reports 15.0 pct passive stake in Protagonist Therapeutics Inc as of Aug. 16.  Full Article

Protagonist Therapeutics shares open at $12.00 in debut
Thursday, 11 Aug 2016 

: Protagonist Therapeutics Inc shares open at $12.00 in debut, flat from the IPO price of $12.00 per share Further company coverage: [PTGX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Protagonist Therapeutics announces pricing of initial public offering
Thursday, 11 Aug 2016 

Protagonist Therapeutics Inc : Protagonist Therapeutics announces pricing of initial public offering .Says initial public offering of 7.50 million common shares priced at $12.00 per share.  Full Article

BRIEF-Protagonist Therapeutics Appoints Sarah Noonberg To Board

* PROTAGONIST THERAPEUTICS APPOINTS SARAH NOONBERG TO THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage: